Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $125 from $115 and keeps a Buy rating on the shares. The views the FDA approval of Icotyde as a “major de-risking event” for the company. The approval transitions Protagonist from development-stage to a “multi-asset, cash-generative platform company,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $119 from $113 at Barclays
- Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
- Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
- Icotyde label upside surprise for Protagonist, says H.C. Wainwright
- Protagonist announces Johnson & Johnson received approval for ICOTYDE